2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure

Published: November 02, 2020

Running through updates on all their patients
  • This document describes performance measures for heart failure that are appropriate for public reporting or pay-for-performance programs.
  • A new safety measure (laboratory monitoring for patients treated with mineralocorticoid receptor antagonists) is paired with a new treatment measure (mineralocorticoid receptor antagonists in patients with heart failure with reduced left ventricular ejection fraction).
  • Other additions to the performance measures include the new medication, sacubitril/valsartan, and use of cardiac resynchronization therapy.